Results for Pembrolizumab as a First-Line Therapy for Advanced Urothelial Carcinoma

May 22, 2017
Arjun Balar, MD

Arjun Balar, MD, assistant professor, Department of Medicine, and director, Genitourinary Medical Oncology Program, NYU Langone Medical Center, discussed results of the KEYNOTE-052 study of pembrolizumab as a first-line therapy for patients with cisplatin-ineligible advanced urothelial cancer.